Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. [electronic resource]
Producer: 20070308Description: 1761-7 p. digitalISSN:- 1744-8328
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Benzenesulfonates -- therapeutic use
- Bevacizumab
- Carcinoma, Renal Cell -- drug therapy
- Chemotherapy, Adjuvant
- Drug Delivery Systems
- Drug Therapy, Combination
- Forecasting
- Humans
- Immunologic Factors -- therapeutic use
- Immunotherapy
- Indoles -- therapeutic use
- Interferon-alpha -- administration & dosage
- Interleukin-2 -- administration & dosage
- Kidney Neoplasms -- therapy
- Neoplasm Proteins -- antagonists & inhibitors
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Protein Kinase Inhibitors -- therapeutic use
- Protein Kinases -- drug effects
- Pyridines -- therapeutic use
- Pyrroles -- therapeutic use
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Sirolimus -- analogs & derivatives
- Sorafenib
- Sunitinib
- TOR Serine-Threonine Kinases
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.